CHMP backs BMS’ first-in-class anaemia drug ReblozylBristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has Share XCHMP backs BMS’ first-in-class anaemia drug Reblozylhttps://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
Acceleron axes clinical development of muscular dystrophy drugAcceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug Share XAcceleron axes clinical development of muscular dystrophy drughttps://pharmaphorum.com/news/acceleron-axes-clinical-development-of-muscular-dystrophy-drug/
